NCT02940314View on ClinicalTrials.gov

Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Overactive Bladder
Interventions
DRUG

HIP1503

DRUG

HGP1103

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02940314 - Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter